{"entity":{"id":"nct06299761","kind":"trial","name":"Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications","aka":[],"tldr":"A phase 1 trial of BBI-825 run by Boundless Bio, Inc., terminated.","summary":"Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications is a phase 1 interventional study registered as NCT06299761 by Boundless Bio, Inc., with 19 participants enrolled, started 2024-03-28. Conditions recorded: Solid Tumor. Interventions recorded: BBI-825.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06299761","url":"https://clinicaltrials.gov/study/NCT06299761"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["bbi-825"],"companies":["boundless-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06299761","phase":"1","setting":"An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-825 and BBI-825 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Resistance Gene Amplifications","sponsor":"Boundless Bio, Inc.","enrolled":19,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06299761/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"bbi-825","kind":"drug","name":"BBI-825","route":"/drugs/bbi-825/"}],"company":[{"id":"boundless-bio","kind":"company","name":"Boundless Bio","route":"/companies/boundless-bio/"}]}}